|
|
| Kaynak: Yahoo Finance Ekleyen: Tipi Ergün 05-10-2017 09:30:46 |  CAMBRIDGE, Mass.--(BUSINESS WIRE)--
H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, announced today that Lihua Yu, Ph.D., has been promoted to Chief Data Sciences Officer (CDSO). Dr. Yu previously served as H3 Biomedicine’s Vice President, Data Science and Information Technology.
Tümünü Oku |
| | | | | | | | |
|
